Alumis completes merger with Acelyrin

Written by Emily J. Thompson, Senior Investment Analyst

SLRN%

ALMS-1.28%

Updated: May 21 2025

0mins

Merger Completion: Alumis has successfully merged with ACELYRIN, resulting in ACELYRIN stockholders receiving 0.4814 shares of Alumis common stock for each share they owned.
Stock Trading Status: Following the merger, ACELYRIN common stock has ceased trading and is no longer listed on the NASDAQ Global Select Market.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Alumis completes merger with Acelyrin

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Medtronic to Spin Off Diabetes Unit, Focus on Profitable Growth

Apple's New MacBook Pro Launching in 2026 with M5 Pro and M5 Max Chips

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch